Biosimilars and Follow-On Biologics: World Market 2013-2023
2
Page 67 www.visiongain.com Biosimilars and Follow-On Biologics: World Market 2013-2023 4.4.8 France: Biosimilars Submarket 2013-2023 Compared with other leading Western European nations, pharmaceutical spending, per capita, is high in France, while generic drug use is low. In France, low uptake of generics is a result of comparatively low prices for branded drugs, as well as many patents for leading products being extended in the country. Low uptake of generics is matched there by low uptake of biosimilars, when compared other leading nations such as the UK and Germany. In France, biosimilars account for only around 15% of prescriptions in the EPO, filgrastim and somatropin markets. For EPO, the level of biosimilar uptake is estimated to be just 5%. In that submarket, as well as for growth hormones, low uptake is the result of mandatory price reductions for the reference biologics and biosimilars. These price reductions mean that there is little difference between the cost of the reference biologic and the biosimilar. Generally speaking, though, biosimilars are launched at a discount of 20% over the reference biologics in France. Reports suggest that doctors in France have not yet gained confidence in prescribing biosimilars, giving another possible explanation as to why uptake remains low. The reason given is that biosimilars are relatively new to the market - confidence in these drugs will grow in the coming 10 years, visiongain predicts. This growing confidence will drive revenues to $321m in 2017, up from $61m in 2012 (Table 4.9 and Figure 4.9). Growth in the second half of the forecast period will be driven by the launch of biosimilar mAbs. By 2023, the French biosimilars submarket will be worth $1,146m, having grown since 2012 with a CAGR of 30.6%. Visiongain predicts that France will fall further behind Germany, in terms of market size, although its European market share will increase relative to that country. 2012 2013 2014 2015 2016 2017 Submarket ($m) 61 75 119 170 236 321 Annual Growth (%) 23 58 44 39 36 CAGR (%) 39.4 2018 2019 2020 2021 2022 2023 Submarket ($m) 423 547 682 832 977 1,146 Annual Growth (%) 32 29 25 22 18 17 CAGR (%) 23.7 Source: visiongain 2013 Table 4.9 French Biosimilars Submarket: Revenue Forecast, 2012- 2023
-
Upload
visiongain -
Category
Health & Medicine
-
view
369 -
download
1
description
For more information on this report please contact [email protected] (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1039/Biosimilars-And-Follow-On-Biologics-World-Market-2013-2023
Transcript of Biosimilars and Follow-On Biologics: World Market 2013-2023
Page 67
www.visiongain.com
Biosimilars and Follow-On Biologics: World Market 2013-2023
4.4.8 France: Biosimilars Submarket 2013-2023 Compared with other leading Western European nations, pharmaceutical spending, per capita, is
high in France, while generic drug use is low. In France, low uptake of generics is a result of
comparatively low prices for branded drugs, as well as many patents for leading products being
extended in the country. Low uptake of generics is matched there by low uptake of biosimilars,
when compared other leading nations such as the UK and Germany. In France, biosimilars
account for only around 15% of prescriptions in the EPO, filgrastim and somatropin markets. For
EPO, the level of biosimilar uptake is estimated to be just 5%. In that submarket, as well as for
growth hormones, low uptake is the result of mandatory price reductions for the reference biologics
and biosimilars. These price reductions mean that there is little difference between the cost of the
reference biologic and the biosimilar. Generally speaking, though, biosimilars are launched at a
discount of 20% over the reference biologics in France.
Reports suggest that doctors in France have not yet gained confidence in prescribing biosimilars,
giving another possible explanation as to why uptake remains low. The reason given is that
biosimilars are relatively new to the market - confidence in these drugs will grow in the coming 10
years, visiongain predicts. This growing confidence will drive revenues to $321m in 2017, up from
$61m in 2012 (Table 4.9 and Figure 4.9). Growth in the second half of the forecast period will be
driven by the launch of biosimilar mAbs. By 2023, the French biosimilars submarket will be worth
$1,146m, having grown since 2012 with a CAGR of 30.6%. Visiongain predicts that France will fall
further behind Germany, in terms of market size, although its European market share will increase
relative to that country.
2012 2013 2014 2015 2016 2017
Submarket ($m) 61 75 119 170 236 321
Annual Growth (%) 23 58 44 39 36
CAGR (%) 39.4
2018 2019 2020 2021 2022 2023
Submarket ($m) 423 547 682 832 977 1,146
Annual Growth (%) 32 29 25 22 18 17
CAGR (%) 23.7
Source: visiongain 2013
Table 4.9 French Biosimilars Submarket: Revenue Forecast, 2012-2023
Page 68
www.visiongain.com
Biosimilars and Follow-On Biologics: World Market 2013-2023
4.4.9 Biosimilar Uptake is High in the UK In 2012, biosimilar revenues in the UK totalled $40m, accounting for 12.5% of the EU biosimilars
submarket. Uptake for biosimilars in the UK is higher than for France, with around two thirds of
NHS filgrastim prescriptions being filled with biosimilars. Price and cost effectiveness are two
important features of the UK pharmaceutical market, visiongain notes. However, upon launch
discounts for biosimilars are not as high as has been seen in other countries. For example, In July
2009, Sandoz’ Zarzio was launched on the UK market with a 10% discount over Neupogen,
although this may be the result of a low price for the reference biologic. Pricing is a key element of
entering the UK market, with only drugs found to be cost-effective - as determined by the criteria of
the National Institute for Health and Care Excellence (NICE) - available through the NHS. While
generic drugs are exempt from pricing regulation schemes in the UK, biosimilars are covered.
As with other leading European markets, biosimilar substitution is not possible in the EU. The UK
Medicines and Healthcare Products Regulatory Agency (MHRA) has introduced a number of
safeguards to prevent against accidental substitution. In 2008, for example, it advised that doctors
should always prescribe biological drugs by brand name to avoid confusion for the pharmacist. In
addition, packaging for biosimilars in the UK must be printed with a black triangle to identify the
product as a follow-on biologic. The UK was among the first countries to introduce such a
regulation, although similar EU-wide rules are set to take effect in 2013.
0
200
400
600
800
1,000
1,200
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Mar
ket
Size
($m
)
Year
Figure 4.9 French Biosimilars Submarket: Revenue Forecast, 2012-2023
Source: visiongain 2013
